title: [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
abstract: OBJECTIVE
  To evaluate the results of infliximab therapy, an anti-TNF-alpha antibody, in patients with severe and refractory Crohn's disease or with fistulas, treated outside the setting of a therapeutic trial.
  
  
  METHODS
  All Crohn's disease patients treated at the Departments of Gastroenterology of the University Hospitals of Bordeaux, Nantes, Poitiers, Rennes and Tours were retrospectively analyzed.
  
  
  RESULTS
  Sixty-nine patients were treated with a total of 170 infusions of infliximab, 32 patients being treated for refractory Crohn's disease and 37 for fistulas. The median follow-up was 8 months (extremes 1-20). An objective response was observed in 79% of refractory Crohn's disease patients and 78% of fistulazing patients. A remission was observed in 72% and 70% of the patients respectively. Forty-five percent of patients had relapsed within 4 months (extremes 2-7). Immunosuppressive therapy was associated with a lower relapse rate (18% with versus 56% without, P=0.004). Infliximab resulted in a steroid-sparing effect in 73% of patients. Forty adverse events, none of severe grade, were observed in 22% of the patients, without any influence of steroids or immunosuppressive therapy.
  
  
  CONCLUSIONS
  This study confirms that infliximab is very effective in steroid-dependent and fistulazing Crohn's disease. Infliximab has a steroid-sparing effect and immunosuppressive therapy is associated with a reduced relapse rate. Although the tolerance is good in the short term, long term safety remains to be established by further studies.
authors.affiliation: Hépato-Gastroentérologie, Hôtel-Dieu, Nantes.
authors.forename: Marie
authors.initials: M
authors.lastname: Doubremelle
authors.forename: Arnaud
authors.initials: A
authors.lastname: Bourreille
authors.forename: Frank
authors.initials: F
authors.lastname: Zerbib
authors.forename: Denis
authors.initials: D
authors.lastname: Heresbach
authors.forename: Etienne Henry
authors.initials: EH
authors.lastname: Metman
authors.forename: Philippe
authors.initials: P
authors.lastname: Beau
authors.forename: Jérôme
authors.initials: J
authors.lastname: Gournay
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Galmiche
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab